AbbVie said on Friday that the U.S. Food and Drug Administration approved its drug for complicated intra-abdominal infections ...

Drugmaker Pfizer posted a better-than-expected fourth-quarter profit on Thursday, helped by cost cuts it began last year as ...

(Reuters) -Drugmaker Pfizer posted a better than expected fourth quarter profit on Thursday, helped by cost cuts and a ...

The results cap off a critical year for Pfizer, which has been slashing costs as it recovers from the rapid decline of its ...

The pharmaceutical giant named Jeffrey Legos the head of a division it is counting on to overcome investor pressure and grow ...

Last year marked the first time in Pfizer’s 175-year history that the drugmaker shelled out the requisite millions for ...

Pfizer's Q4 2024 earnings beat expectations, but concerns over 2025 guidance and patent expirations led to stock decline. See ...

Pfizer reported robust fourth-quarter 2024 earnings, exceeding expectations in both revenue and adjusted earnings.

Pfizer CEO Albert Bourla said there are "opportunities that probably outweigh the risks" of the Trump administration's ...

Pfizer has ended development of a B7-H4-directed antibody-drug conjugate (ADC), triggering a $1 billion impairment charge. | ...

In mid-2024, the commercial president of Pfizer’s oncology unit Suneet Varma announced his retirement after 15 years with the ...

Unexpected demand for Pfizer Inc.’s Covid vaccine helped the company beat quarterly expectations. Then Robert F. Kennedy Jr., ...